BlackStar Enterprise Group Inc (BEGI)

[Bubae]

Wow, You are welcome. A rare complement and I have been using the numbers to point out the dilution since this was trading above a penny. The most insidious part about all of this isn't that the toxic lenders are making many hundreds of thousands while Blackstar gets a pittance of debt relief. The worst part is that the CEO himself is marketing these conversions through the infomercials which are also paid for with shares.

You can see from the filings that 698,077,221 less the 104,643,939 shares for Q1 or 593,433,282 shares for conversion were queued up for the promotional period representing relatively little debt relief. Those shares would have likely waited for the October method patent news because the trading price had been so low for months. As low as $0.0001 just days before the beginning of the run up. This would mean that the actual float could have been around 700 million shares or so in October. Meanwhile they borrowed another $400K with notes with maturity dates of less than a year. That is a subject for another post.


During the three months ended March 31, 2023, the Company issued shares of its common stock as follows:
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001483646/000106594923000051/begi-20230331.htm.htm

As of May 5, 2023, there were 683,446,845 shares of the registrant’s common stock, $0.001 par value, issued and outstanding, not including shares reserved for conversion of notes.

• 104,643,939 shares for conversion of $33,927 principal and interest on convertible notes payable.

For the quarterly period ended September 30, 2023
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001483646/000106594923000100/begi-20230930.htm

NOTE 5 – STOCKHOLDERS’ DEFICIT
Common Stock During the nine months ended September 30, 2023, the Company issued shares of its common stock as follows:

• 698,077,221 shares for conversion of $116,725 principal and interest on convertible notes payable.

For the fiscal year ended December 31, 2023
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001483646/000106594924000044/begi-20231231.htm

NOTE 5 – STOCKHOLDERS’ DEFICIT (continued)
Common Stock
Page F-11
During the year ended December 31, 2023, the Company issued shares of its common stock as follows:

• 845,162,311 shares for conversion of $200,432 principal and interest on convertible note payable.
  
• 71,250,000 shares valued at $266,063 as consideration for financing fees for loans made to the Company.
  
• 25,000,000 shares valued at $100,000 ($0.004 per share) as partial consideration for a media consulting contract.
  
• 56,788,923 shares for exercise of previously issued warrants at $0.0128 per share. The exercise price was revised to $0.00062 per share from $0.25 per share as per antidilution provision of the warrant agreement. The warrants were exercised on a cashless or “net” basis...

Page F-19
NOTE 12 – SUBSEQUENT EVENTS
In 2024, GS Capital filed notices of conversion and were issued, in three tranches, 195,620,499 shares of the Company’s common stock at a price of $0.00006 per share on their note of October 11, 2021. (See Notes 7 and 11)

Page 57
In 2023, we received $400,000 in non-convertible debt financing from non-related individuals, of which $325,000 is due within one year of issuance with interest at 11% per annum, and $75,000 is due from 2025 to 2026 with interest at 5.5% per annum. As consideration for entering the note agreements in 2023, the Company issued to note holders an aggregate 71,250,000 shares of its common stock, valued at $266,063. In 2022, substantially all of our funding has been from convertible debt financings.